drugset / Trial / NCT06231017
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab plus cetuximab and chemotherapy for patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer.
Timeline
- Start
- 2024-01-19
- Primary completion
- 2025-01-19
- Completion
- 2026-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Cetuximab | Monoclonal antibody | 500 mg | — |